Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 59, 3077-3083, July 1, 1999]
© 1999 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henkels, K. M.
Right arrow Articles by Turchi, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henkels, K. M.
Right arrow Articles by Turchi, J. J.
[Cancer Research 59, 3077-3083, July 1, 1999]
© 1999 American Association for Cancer Research


Biochemistry

Cisplatin-induced Apoptosis Proceeds by Caspase-3-dependent and -independent Pathways in Cisplatin-resistant and -sensitive Human Ovarian Cancer Cell Lines1

Karen M. Henkels and John J. Turchi2

Department of Biochemistry and Molecular Biology, Wright State University School of Medicine, Dayton, Ohio 45435

We have assessed in detail the effect of cisplatin-activated programmed cell death in the cisplatin-sensitive human ovarian cancer cell line A2780 and two drug-resistant subclones, CP70 and C30. To determine whether the differential extent of apoptosis observed between the sensitive and resistant ovarian cancer cell lines was the result of dissimilar upstream signaling events, we assessed the execution of apoptotic events that precede target protein proteolysis and subsequent chromosomal DNA degradation. Proteolytic degradation of procaspase-3 was observed in both the CP70 and C30 cells following IC50 cisplatin treatment, whereas no proteolyzed caspase-3 subunits were detected in the A2780 cells. However, using a direct enzymatic assay measuring cleavage of the synthetic peptide substrate (N-acetyl-Asp-Glu-Val-Asp-p-nitroanilide), activity was detected in extracts prepared from A2780 cells treated at the IC90 level of cisplatin and was 2–3-fold less than that of extracts prepared from CP70 and C30 cells. Because the activation of procaspase-3 by caspase-9 requires the release of cytochrome c into the cytoplasm, we determined the level of cytoplasmic cytochrome c in each cell line in response to cisplatin treatment. Consistent with the caspase-3 activation data, a very small increase in cytoplasmic cytochrome c was observed in A2780 cells following cisplatin treatment, whereas dramatic increases were evident in both the CP70 and C30 cell lines. The expression of the mitochondrial factors Bcl-2, Bcl-x, and Bax was determined because each has been implicated in the regulation or release of cytochrome c at the level of the mitochondria. Bcl-2 and Bcl-xL proteins remained relatively unchanged in expression for over 48 h after exposure to cisplatin in the A2780 cell lines. However, within the same time period, expression of Bcl-2 decreased in the CP70- and C30-resistant cell lines, whereas an increase in Bcl-xL expression was observed. Expression of the proapoptotic Bcl-xS protein was observed in only the resistant CP70 and C30 cell lines independent of cisplatin treatment. A change in the expression of Mr 24,000 Bax to a Mr 21,000 isoform was evidenced in the A2780 cells within 48 h of cisplatin treatment and, to a greater extent, in the CP70 and C30 cells, which also expressed a Mr 16,000 Bax variant. Evidence for an alternative apoptotic pathway in A2780 cells was obtained by demonstrating increased FADD expression in response to cisplatin treatment. These results support a model in which cisplatin-induced programmed cell death in the cisplatin-sensitive A2780 and -resistant CP70 and C30 cells proceeds via caspase-3-independent and -dependent pathways, respectively.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
M. Muscolini, R. Cianfrocca, A. Sajeva, S. Mozzetti, G. Ferrandina, A. Costanzo, and L. Tuosto
Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells
Mol. Cancer Ther., June 1, 2008; 7(6): 1410 - 1419.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
Q. Zhong, Y.-J. Wen, H.-S. Yang, H. Luo, A.-F. Fu, F. Yang, L.-J. Chen, X. Chen, X.-R. Qi, H.-G. Lin, et al.
Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice
Ann. Onc., April 23, 2008; (2008) mdn167v1.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. A. G. M. Cillessen, J. C. Reed, K. Welsh, C. Pinilla, R. Houghten, E. Hooijberg, J. Deurhof, K. C. M. Castricum, P. Kortman, C. J. Hess, et al.
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells
Blood, January 1, 2008; 111(1): 369 - 375.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. A.G.M. Cillessen, C. J. Hess, E. Hooijberg, K. C.M. Castricum, P. Kortman, F. Denkers, W. Vos, M. A. van de Wiel, G. J. Schuurhuis, G. J. Ossenkoppele, et al.
Inhibition of the Intrinsic Apoptosis Pathway Downstream of Caspase-9 Activation Causes Chemotherapy Resistance in Diffuse Large B-Cell Lymphoma
Clin. Cancer Res., December 1, 2007; 13(23): 7012 - 7021.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. S. Razzaque
Cisplatin nephropathy: is cytotoxicity avoidable?
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2112 - 2116.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Zhang and X. Shen
Heat Shock Protein 27 Protects L929 Cells from Cisplatin-Induced Apoptosis by Enhancing Akt Activation and Abating Suppression of Thioredoxin Reductase Activity
Clin. Cancer Res., May 15, 2007; 13(10): 2855 - 2864.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S. Tarang, A. Sodhi, and P. Chauhan
Differential expression of Toll-like receptors in murine peritoneal macrophages in vitro on treatment with cisplatin
Int. Immunol., May 1, 2007; 19(5): 635 - 643.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Lebrun, M. R. Montminy, and E. Van Obberghen
Regulation of the Pancreatic Duodenal Homeobox-1 Protein by DNA-dependent Protein Kinase
J. Biol. Chem., November 18, 2005; 280(46): 38203 - 38210.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
H.-C. YEN, Y.-C. TANG, F.-Y. CHEN, S.-W. CHEN, and H. J. MAJIMA
Enhancement of Cisplatin-Induced Apoptosis and Caspase 3 Activation by Depletion of Mitochondrial DNA in a Human Osteosarcoma Cell Line
Ann. N.Y. Acad. Sci., May 1, 2005; 1042(1): 516 - 522.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
H. J. Boeckman, K. S. Trego, and J. J. Turchi
Cisplatin Sensitizes Cancer Cells to Ionizing Radiation via Inhibition of Nonhomologous End Joining
Mol. Cancer Res., May 1, 2005; 3(5): 277 - 285.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
K. Anderson, K. A. Lawson, M. Simmons-Menchaca, L. Sun, B. G. Sanders, and K. Kline
{alpha}-TEA Plus Cisplatin Reduces Human Cisplatin-Resistant Ovarian Cancer Cell Tumor Burden and Metastasis
Experimental Biology and Medicine, December 1, 2004; 229(11): 1169 - 1176.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. C. Pingle, S. Mishra, A. Marcuzzi, S. G. Bhat, Y. Sekino, L. P. Rybak, and V. Ramkumar
Osmotic Diuretics Induce Adenosine A1 Receptor Expression and Protect Renal Proximal Tubular Epithelial Cells against Cisplatin-mediated Apoptosis
J. Biol. Chem., October 8, 2004; 279(41): 43157 - 43167.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. C. Han, M.-Y. Lee, K. D. Shin, S. B. Jeon, J. M. Kim, K.-H. Son, H.-C. Kim, H.-M. Kim, and B.-M. Kwon
2'-Benzoyloxycinnamaldehyde Induces Apoptosis in Human Carcinoma via Reactive Oxygen Species
J. Biol. Chem., February 20, 2004; 279(8): 6911 - 6920.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
K. M. Anderson, W. Alrefai, P. Bonomi, T. M. Seed, P. Dudeja, Y. Hu, and J. E. Harris
Caspase-Dependent and -Independent Panc-1 Cell Death Due to Actinomycin D and MK 886 Are Additive but Increase Clonogenic Survival
Experimental Biology and Medicine, September 1, 2003; 228(8): 915 - 925.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Nowak
Protein Kinase C-alpha and ERK1/2 Mediate Mitochondrial Dysfunction, Decreases in Active Na+ Transport, and Cisplatin-induced Apoptosis in Renal Cells
J. Biol. Chem., November 1, 2002; 277(45): 43377 - 43388.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. E. Chalfant, K. Rathman, R. L. Pinkerman, R. E. Wood, L. M. Obeid, B. Ogretmen, and Y. A. Hannun
De Novo Ceramide Regulates the Alternative Splicing of Caspase 9 and Bcl-x in A549 Lung Adenocarcinoma Cells. DEPENDENCE ON PROTEIN PHOSPHATASE-1
J. Biol. Chem., April 5, 2002; 277(15): 12587 - 12595.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
Q. Huang, R. T. Dunn II, S. Jayadev, O. DiSorbo, F. D. Pack, S. B. Farr, R. E. Stoll, and K. T. Blanchard
Assessment of Cisplatin-Induced Nephrotoxicity by Microarray Technology
Toxicol. Sci., October 1, 2001; 63(2): 196 - 207.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
V. M. Gonzalez, M. A. Fuertes, C. Alonso, and J. M. Perez
Is Cisplatin-Induced Cell Death Always Produced by Apoptosis?
Mol. Pharmacol., April 1, 2001; 59(4): 657 - 663.
[Full Text]


Home page
Cancer Res.Home page
R. N. Winter, A. Kramer, A. Borkowski, and N. Kyprianou
Loss of Caspase-1 and Caspase-3 Protein Expression in Human Prostate Cancer
Cancer Res., February 1, 2001; 61(3): 1227 - 1232.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
Y. Mitsuuchi, S. W. Johnson, M. Selvakumaran, S. J. Williams, T. C. Hamilton, and J. R. Testa
The Phosphatidylinositol 3-Kinase/AKT Signal Transduction Pathway Plays a Critical Role in the Expression of p21WAF1/CIP1/SDI1 Induced by Cisplatin and Paclitaxel
Cancer Res., October 1, 2000; 60(19): 5390 - 5394.
[Abstract] [Full Text]


Home page
JNCI J Natl Cancer InstHome page
P. Costantini, E. Jacotot, D. Decaudin, and G. Kroemer
Mitochondrion as a Novel Target of Anticancer Chemotherapy
J Natl Cancer Inst, July 5, 2000; 92(13): 1042 - 1053.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Schuler, E. Bossy-Wetzel, J. C. Goldstein, P. Fitzgerald, and D. R. Green
p53 Induces Apoptosis by Caspase Activation through Mitochondrial Cytochrome c Release
J. Biol. Chem., March 15, 2000; 275(10): 7337 - 7342.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Fujii, M. L. Garcia-Bermejo, J. L. Bernabo, J. Caamano, M. Ohba, T. Kuroki, L. Li, S. H. Yuspa, and M. G. Kazanietz
Involvement of Protein Kinase C delta (PKCdelta ) in Phorbol Ester-induced Apoptosis in LNCaP Prostate Cancer Cells. LACK OF PROTEOLYTIC CLEAVAGE OF PKCdelta
J. Biol. Chem., March 10, 2000; 275(11): 7574 - 7582.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1999 by the American Association for Cancer Research.